One study reported BCL3 as prognostic for improved survival in a specific subtype of triple negative breast cancer patients and in a representative cell line, where BCL3 was shown to improve responses to paclitaxel, while still displaying its conventional oncogenic role in promoting proliferation. Here, BCL3 is linked to triple-negative breast carcinoma.